0GTN.LSE BioGaia AB ser. B

Healthcare Commercial Services & Supplies London Exchange
- SEK
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
1.52%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.

Is 0GTN.LSE undervalued?

Graham number

The Graham number of BioGaia AB ser. B cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioGaia AB ser. B fundamental analysis

No fundamental analysis for BioGaia AB ser. B yet.

BioGaia AB ser. B stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioGaia AB ser. B

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. I…

Full company profile